Full-Time

KOL & External Engagement Platforms Senior Manager

Global Capability Owner

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

Compensation Overview

$140.8k - $211.2k/yr

+ Bonus + Equity Grants

Pennsylvania, USA

Remote

Remote within the United States; 20-30% travel.

Bachelor's, MBA

Category
Biology & Biotech (1)
Required Skills
Product Management
Data Analysis

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Requirements
  • Bachelor’s degree in business, technology, marketing, science, or related field.
  • 6+ years of experience in pharmaceutical, healthcare, or other highly regulated industries
  • Experience in digital product management, product ownership, or demonstrated experience managing the creation and delivery of a product roadmap within a cross-functional team.
  • Experience working with event and engagement management platforms, engagement tools, and vendor-supported engagement solutions.
  • 20 to 30% travel will be required.
Responsibilities
  • Define the product vision and outcomes aligned to global and franchise priorities in collaboration with key stakeholders ensuring platforms strengthen Jazz’s credibility with the medical community.
  • Lead the ongoing evolution of the KOL & External Engagement Platforms roadmap, making prioritization and trade-off decisions to add the most value based upon objective data and user feedback.
  • Translate business needs into product solutions with measurable success metrics that drive impact across franchises and the business.
  • Drive delivery of a global roadmap that sequences platform governance, workflow improvements, and engagement capability enhancements across the Customer Engagement Platform (Patient, Caregiver, HCP, Healthcare Organizations), and related tools to improve execution efficiency, event performance tracking, and compliant KOL engagement at scale.
  • Connect business stakeholders (e.g., franchises, regions, finance, contracting) with the KOL & External Engagement Platforms global capability team, ensuring requirements are clearly defined and aligned to strategically important business outcomes and success metrics.
  • Partner closely with the Global Capability Owner and Tech Leads to align business priorities with technical feasibility and delivery sequencing, ensuring trade-offs support agreed business outcomes.
  • Partner closely with the Suite Lead to align product priorities, scope and roadmap decisions with team-level business objectives, ensuring consistent focus on enterprise outcomes and value delivery.
  • Define clear product requirements, user stories, and acceptance criteria to enable efficient execution and alignment with business partner activity needs.
  • Partner across the Customer Experience Organization to support seamless integration and ongoing product evolution to support scalability, flexibility, and compliance requirements
  • Drive more impactful engagement and measurable outcomes by enabling scalable planning, execution, and measurement of external activities and programs.
  • Design scalable approach to KOL identification, end-to-end co-creation workflow and annual planning, aligning systems and tools to facilitate a global approach.
  • Apply user insights and engagement data to inform the design and evolution of KOL & External Engagement Platform capabilities that enhance the customer experience for both internal and external users.
  • Participate in and support discovery efforts, engaging directly with users and key stakeholders to deeply understand their needs, validate business value, and assess technical feasibility prior to development
  • Partner across Global Capability product teams to deliver scalable, reusable KOL & External Engagement Platforms capabilities.
  • Monitor product adoption, outcome KPIs and engagement metrics to inform backlog prioritization and continuous improvement.
  • Manage documentation of (PRDs, user stories, discovery artifacts), and sprint planning in partnership with the Tech Lead and development teams.
  • Contribute to experimentation to improve Customer Engagement Platform (Patient, Caregiver, HCP, Healthcare Organizations) outcomes.
  • Leverage outcome metrics to articulate the product's value proposition and its impact, promoting product awareness across CX operations and foster a culture of engagement and feedback in partnership with Activation.
Desired Qualifications
  • Advanced degree (MBA or relevant graduate degree) preferred.
  • Experience working in a product operating model.
  • Experience partnering with Product teams supporting digital and operational capabilities.
  • Advanced degrees may offset a portion of required years of experience, consistent with global hiring guidelines.
  • Experience working in rare disease or specialty brands, with strong understanding of unique stakeholder dynamics.

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue hit $1.21 billion, and guidance rose to $4.75 billion.
  • Zepzelca grew 60% in Q1 2026 on first-line maintenance adoption.
  • Zanidatamab gained FDA Priority Review, positioning Jazz for a near-term oncology launch.

What critics are saying

  • Granules settlement allows a Xywav generic under certain conditions after March 2026.
  • Jazz still carries $4.35 billion debt, with $1.0 billion 2030 notes now exchangeable.
  • Zanidatamab faces an August 25, 2026 PDUFA; rejection cripples launch expectations.

What makes Jazz Pharmaceuticals unique

  • Xywav dominates narcolepsy and idiopathic hypersomnia through low-sodium oxybate differentiation.
  • Jazz owns scarce neurology and oncology assets, including Epidiolex, Zepzelca, and Ziihera.
  • Actio acquisition on August 10, 2026 extends its rare-epilepsy precision medicine franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Yahoo Finance
Aug 11th, 2026
Jazz Pharmaceuticals Q2 revenue beats estimates at $1.21B, ups guidance to $4.68B

Jazz Pharmaceuticals reported a strong second quarter with revenue of $1.21 billion, beating analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion from $4.38 billion. CEO Renée Galá attributed the performance to strong demand for flagship products like Xywav and Epidiolex, alongside accelerating uptake of new oncology therapies. Operating margin improved to 20.5%, up from negative 65.6% in the prior year quarter. However, adjusted earnings per share of $5.71 missed analyst expectations of $6.18. During the earnings call, analysts focused on Epidiolex's growth drivers, Xywav's sustainability amid potential generic competition, and zanidatamab's upcoming approval prospects.

Yahoo Finance
Aug 11th, 2026
Jazz Pharma raises 2026 guidance on record Q2 revenue of $1.2B, up 16%

Jazz Pharmaceuticals reported record second quarter revenue of $1.2 billion, representing 16% year-over-year growth. The company raised its full-year revenue guidance based on strong first-half performance. Chief executive officer Renée Galá attributed the results to execution across the company's diversified portfolio and sustained demand for its commercial products. The company is preparing to launch zanidatamab, with a PDUFA date of 25 August for treatment of first-line HER2-positive metastatic gastroesophageal adenocarcinoma. The earnings call included updates from senior leadership, including chief commercial officer Samantha Pearce, global head of research and development Robert Iannone, and chief financial officer Philip Johnson. Jazz Pharmaceuticals highlighted progress on its long-term value creation priorities whilst maintaining focus on current commercial operations.

Yahoo Finance
Aug 10th, 2026
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront, adding KCNT1+ epilepsy therapy

Jazz Pharmaceuticals has agreed to acquire Actio Biosciences for $820 million upfront and up to $500 million in contingent payments. The deal adds ABS-1230, a clinical-stage precision therapy for KCNT1+ epilepsy, to Jazz's rare epilepsy portfolio. KCNT1+ epilepsy is a rare genetic condition affecting approximately 2,500 patients in the United States. Patients typically experience dozens to hundreds of seizures daily that resist standard medications. Around 80% of cases begin in infancy, with many children unable to reach basic developmental milestones. There are currently no FDA-approved therapies for KCNT1+ epilepsy. ABS-1230 recently showed meaningful seizure reductions in an early clinical trial. The ongoing Phase 1b/2a KYRON trial is designed as the registrational study supporting US new drug application submission.

Yahoo Finance
Aug 5th, 2026
Jazz Pharmaceuticals hits $1.2B quarterly revenue, raises full-year guidance to $4.75B on oncology surge

Jazz Pharmaceuticals reported record quarterly revenue of $1.2 billion for Q2 2026, marking a 16% year-over-year increase driven by double-digit growth across all key promoted brands. The oncology portfolio grew 32% year-over-year, supported by rapid adoption of Zepzelca in first-line maintenance and the successful launch of Modeyso. Xywav demonstrated 13% revenue growth as its low-sodium profile continues to differentiate it from high-sodium generics. The company raised its full-year revenue guidance to $4.60 billion–$4.75 billion. Jazz anticipates the 25 August PDUFA date for zanidatamab in first-line HER2-positive gastric cancers, with commercial teams prepared for immediate launch. The company is leveraging its biliary tract cancer infrastructure to support the zanidatamab rollout. Non-GAAP adjusted gross margin declined slightly due to higher sales mix of royalty-bearing products.

Yahoo Finance
Jun 23rd, 2026
Jazz Pharmaceuticals' lung cancer drug fails trial but investors spared as focus shifts to first-line treatment

Jazz Pharmaceuticals' phase 3 trial evaluating Zepzelca in second-line small-cell lung cancer failed to meet its primary endpoint of overall survival. However, the setback's impact may be limited as Zepzelca's commercial focus has already shifted. In 2025, the FDA granted full approval to Zepzelca combined with Roche's Tecentriq as a first-line maintenance treatment for extensive-stage small-cell lung cancer. That approval demonstrated a 46% reduction in disease progression risk and a 27% reduction in death risk compared with Tecentriq alone. Zepzelca sales increased 60% year over year to approximately $101 million in Q1 2026, driven by first-line maintenance adoption. The drug contributed only 7% of Jazz's total 2025 revenue of $4.3 billion, with neurological medications Xywav and Epidiolex generating significantly larger sales.